Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine R Tuttle

Showing results (21-30 of 355) with videos related to

Pageof 36
Sort By:
Clinical Journal of the American Society of Nephrology : CJASN|May 26, 2018
Race in America: What Does It Mean for Diabetes and CKD?Katherine R Tuttle
The Journal of Clinical Investigation|March 1, 2023
Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitorsKatherine R Tuttle
Current Hypertension Reports|January 8, 2008
Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?Radica Alicic, Katherine R Tuttle
Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2025
Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic ComplicationsJaime Uribarri, Katherine R Tuttle
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2026
Reimagining Nephrology Training in a Cardiovascular-Kidney-Metabolic FrameworkKatherine R Tuttle, Gabriel Danovitch
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Advanced glycation end products and nephrotoxicity of high-protein dietsJaime Uribarri, Katherine R Tuttle
Current Opinion in Nephrology and Hypertension|October 16, 2004
Atherosclerotic renal artery stenosis: current status and future directionsNadia Zalunardo, Katherine R Tuttle
Lancet (London, England)|August 30, 2022
SGLT2 inhibitors as the bedrock of therapy for heart failureKatherine R Tuttle, Janani Rangaswami
The New England Journal of Medicine|May 8, 2014
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney diseaseJonathan Himmelfarb, Katherine R Tuttle
JAMA Cardiology|November 8, 2025
Prerenalism-A Gap That Costs Lives, Hearts, and KidneysJanani Rangaswami, Katherine R Tuttle
Pageof 36

Showing results (21-30 of 355) with videos related to

Sort By:
Pageof 36
Clinical Journal of the American Society of Nephrology : CJASN|May 26, 2018
Race in America: What Does It Mean for Diabetes and CKD?Katherine R Tuttle
The Journal of Clinical Investigation|March 1, 2023
Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitorsKatherine R Tuttle
Current Hypertension Reports|January 8, 2008
Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?Radica Alicic, Katherine R Tuttle
Clinical Journal of the American Society of Nephrology : CJASN|August 8, 2025
Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic ComplicationsJaime Uribarri, Katherine R Tuttle
Clinical Journal of the American Society of Nephrology : CJASN|July 1, 2026
Reimagining Nephrology Training in a Cardiovascular-Kidney-Metabolic FrameworkKatherine R Tuttle, Gabriel Danovitch
Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Advanced glycation end products and nephrotoxicity of high-protein dietsJaime Uribarri, Katherine R Tuttle
Current Opinion in Nephrology and Hypertension|October 16, 2004
Atherosclerotic renal artery stenosis: current status and future directionsNadia Zalunardo, Katherine R Tuttle
Lancet (London, England)|August 30, 2022
SGLT2 inhibitors as the bedrock of therapy for heart failureKatherine R Tuttle, Janani Rangaswami
The New England Journal of Medicine|May 8, 2014
Bardoxolone methyl in type 2 diabetes and advanced chronic kidney diseaseJonathan Himmelfarb, Katherine R Tuttle
JAMA Cardiology|November 8, 2025
Prerenalism-A Gap That Costs Lives, Hearts, and KidneysJanani Rangaswami, Katherine R Tuttle
Pageof 36